In vivo, TRAIL and TRAIL-based strategies significantly reduce tumor volume of xenograft mouse models of Ewing sarcoma, prevent osteolytic lesions, and increase animal survival [21,22,23]. This evidence concerns the gene TNFSF10 and neoplasm.